Abstract
Background Self-reported information may not accurately capture smoking exposure. We aimed to evaluate whether smoking-associated DNA methylation markers improve urothelial cell carcinoma (UCC) risk prediction.
Methods Conditional logistic regression was used to assess associations between blood-based methylation and UCC risk using two matched case-control samples, N=404 pairs from the Melbourne Collaborative Cohort Study (MCCS) and N=440 pairs from the Women’s Health Initiative (WHI) cohort, respectively. Results were pooled using fixed-effects meta-analysis. We developed methylation-based predictors of UCC and evaluated their prediction accuracy on two replication datasets using the area under the curve (AUC).
Results The meta-analysis identified associations (P<4.7×10−5) for 29 of 1,061 smoking-associated methylation sites, but these were substantially attenuated after adjustment for self-reported smoking. Nominally significant associations (P<0.05) were found for 387 (36%) and 86 (8%) of smoking-associated markers without/with adjustment for self-reported smoking, respectively, with same direction of association as with smoking for 387 (100%) and 79 (92%) markers. A Lasso-based predictor was associated with UCC risk in one replication dataset in MCCS (N=134, odds ratio per SD [OR]=1.37, 95%CI=1.00-1.90) after confounder adjustment; AUC=0.66, compared with AUC=0.64 without methylation information. Limited evidence of replication was found in the second testing dataset in WHI (N=440, OR=1.09, 95%CI=0.91-1.30).
Conclusions Combination of smoking-associated methylation marks may provide some improvement to UCC risk prediction. Our findings need further evaluation using larger datasets.
Impact DNA methylation may be associated with UCC risk beyond traditional smoking assessment and could contribute to some improvements in stratification of UCC risk in the general population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Australian National Health and Medical Research Council (NHMRC) project grants 209057, 251553, 504711, 1043616 and 1164455. Cohort recruitment was funded by Cancer Council Victoria [http://www.cancervic.org.au/] and VicHealth [https://www.vichealth.vic.gov.au/]. M.C.S. is a recipient of a Senior Research Fellowship from the NHMRC (GTN1155163). The Women's Health Initiative (WHI) program was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Cancer Council Victoria's Human Research Ethics Committee, Melbourne, VIC, Australia, and the Institutional Review Board and Publications and Presentations Committee of WHI - Clinical Coordinating Center in the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: This work was supported by the Australian National Health and Medical Research Council (NHMRC) project grants 209057, 251553, 504711, 1043616 and 1164455. Cohort recruitment was funded by Cancer Council Victoria [http://www.cancervic.org.au/] and VicHealth [https://www.vichealth.vic.gov.au/]. M.C.S. is a recipient of a Senior Research Fellowship from the NHMRC (GTN1155163). The Women’s Health Initiative (WHI) program was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005.
Conflict of interest: The authors declare no potential conflicts of interest.
Data Availability
The data and code that support the findings of this study are available from the corresponding author upon reasonable request.